Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

FGFR genetic alterations predict for response to NVP-BGJ398, a selective pan-FGFR inhibitor in Phase I clinical trials

Guagnano, Vito and Kauffmann, Audrey and Stamm, Christelle and Yao, Yao and Li, Fang and Zhang, Yun and Chen, Zhi and Ito, Moriko and Wilson, Christopher and Woehrle, Simon and Bordas, Vincent and Le Douget, Mickael and Gaither, Larry and Borawski, Jason and Monahan, John and Venkatesan, Kavitha and Bruemmendorf, Thomas and Garcia-Echeverria, Carlos and Hofmann, Francesco and Sellers, William and Graus Porta, Diana (2012) FGFR genetic alterations predict for response to NVP-BGJ398, a selective pan-FGFR inhibitor in Phase I clinical trials. Cancer Discovery, 2 (12). pp. 1118-1133. ISSN 23002168

Abstract

Patient stratification biomarkers that enable the translation of cancer genetic knowledge into clinical utility are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. Here we describe the identification of patient stratification biomarkers for NVP-BGJ398, a novel and selective FGFR inhibitor. By intersecting genome-wide gene expression and genomic alteration data with cell line sensitivity data across an annotated collection of cancer cell lines termed the “Cancer Cell Line Encyclopedia”, we show that genetic alterations for FGFR family members predict for sensitivity to NVP-BGJ398 in specific cancer types, thus providing the rationale for clinical trials in well defined subpopulations of cancer patients with tumors harboring these molecular abnormalities.

Item Type: Article
Date Deposited: 13 Apr 2017 00:45
Last Modified: 13 Apr 2017 00:45
URI: https://oak.novartis.com/id/eprint/7774

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.